Abstracts tagged "urate"

Abstract Number: 1573 • ACR Convergence 2021
Vascular Monosodium Urate Crystal Deposition in Gout: A Dual-energy CT and Microscopy Study of Cadaveric Donors
Nicola Dalbeth¹, Mariam Alhilali¹, Peter Riordan¹, Ravi Narang¹, Ashika Chhana¹, Sue McGlashan¹, Anthony Doyle¹ and MARIANO ANDRES², ¹University of Auckland, Auckland, New Zealand, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Cardiovascular disease is a common comorbidity in people with gout. A hypothesized link between cardiovascular disease and gout is the deposition of monosodium urate…
Abstract Number: 902 • 2019 ACR/ARP Annual Meeting
The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate
Chio Yokose¹, Sharan Rai ², Na Lu ³, Natalie McCormick ⁴, Gary Curhan ⁵ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, ³Massachusetts General Hosptial, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁵Channing Laboratory and Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout and hyperuricemia are associated with cardiometabolic comorbidities and increased risk of premature mortality. Often, low-purine (i.e., low-protein) diets are recommended for patients with…
Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Mats Dehlin¹, Andreas Fasth ², Maximilian Reinhardt ³ and Lennart Jacobsson ⁴, ¹Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ²Medical Affairs, Novartis Sverige AB, Kista, Sweden, Stockholm, Sweden, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].